GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Scientific support for ATryn in DIC/sepsis:

[Following are the most relevant published works, according to the presentation at GTC’s 2006 annual meeting. If anyone has access to the full articles (other than the KyberSept study), please speak up! T.i.a.]


Benefit/Risk Profile of High-Dose
Antithrombin in Patients with Severe
Sepsis Treated With And Without
Concomitant Heparin

Hoffmann, JN et al
Thromb Haemost. 2006 May;95(5):850-6.
Abstract: #msg-10993909.


--
Antithrombin for severe sepsis?
Try again but without the heparin!

Jilma, B
Thromb Haemost. 2006 May;95(5):755.
(No abstract)


--
Treatment effects of high-dose
antithrombin without concomitant
heparin in patients with severe
sepsis with or without disseminated
intravascular coagulation

Kienast J et al
J Thromb Haemost. 2006 Jan;4(1):90-7
Abstract: #msg-9313165.


--
High-dose antithrombin in the treatment
of severe sepsis in patients with a high
risk of death: efficacy and safety

Wiedermann CJ
Crit Care. 2006 Feb 34(2):285-92.
(The abstract of a related piece from
the same author is in #msg-10232620.)


--
Recombinant human antithrombin inhibits
thrombin formation and interleukin-6
release in human endotoxemia

Leitner JM et al
Clin Pharmacol Ther. 2006 Jan;79(1):23-34.
Abstract: #msg-9313029.


--
[The original KyberSept study]

High-dose antithrombin in severe
sepsis: a randomized controlled trial

Warren B et al
JAMA 2001 286:1869
http://scalpel.stanford.edu/articles/AT3.pdf